United States Personalized Medicine Market is expected to reach US$ 976.30 billion by 2031 | Major key players - Abbott, GE HealthCare., Biogen.

Market Size and Growth:

The Global Personalized Medicine Market size reached US$ 538.25 billion in 2023 and is expected to reach US$ 976.30 billion by 2031, growing with a CAGR of 7.8% during the forecast period 2024-2031. The Market is growing due to increasing demand for tailored therapies, advancements in genomics, and rising prevalence of chronic diseases.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/personalized-medicine-market?sz

The Personalized Medicine Market focuses on developing tailored medical treatments based on individual genetic, environmental, and lifestyle factors. It integrates genomics, diagnostics, and targeted therapies to improve disease prevention, diagnosis, and treatment outcomes. This market encompasses precision drugs, biomarker-based therapies, and companion diagnostics, aiming to enhance efficacy, reduce side effects, and transform healthcare from a one-size-fits-all to a patient-specific approach.

Industry Recent Developments:

United States:

✅ In October 2025, the U.S. personalized medicine market emphasizes the integration of advanced digital health, biotechnology, and genomics innovations that are driving highly customized medical therapies tailored to individual patient's genetic makeup and lifestyle, moving healthcare beyond the traditional "one-size-fits-all" approach.

✅ In August 2025, the U.S. personalized medicine market is projected to reach $307.04 billion by 2033, propelled by next-generation sequencing advances, rising patient demand for personalized treatments, chronic disease prevalence, favorable government policies, and increased biotech and digital health investments.

✅ In September 2025, the U.S. market for next-generation sequencing (NGS) experiences significant growth driven by the rising need for customized therapies, with NGS technologies playing a crucial role in generating precise genetic insights for personalized medicine strategies.

Japan:

✅ In October 2025, Japan is advancing personalized medicine by integrating genomics with AI technologies, aiming to revolutionize targeted therapies and enhance precision healthcare outcomes.

✅ In October 2025, the Japan personalized medicine market is forecasted to grow at a CAGR of approximately 5.95% during 2025-2035, fueled by government support under the Healthcare Policy 2025 and the increasing adoption of personalized treatment practices driven by the aging population and chronic disease prevalence.

✅ Japan's hospitals are widely implementing DNA-based diagnostics for personalized cancer treatments, leading to more precise care and improved patient outcomes as of late 2025, responding to the high incidence of chronic diseases like cancer among the Japanese population.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/personalized-medicine-market?sz

FDA Approvals and Personalized Medicine:

The FDA has continued to prioritize personalized medicine, approving several novel therapies in 2025. In the first half of the year, 16 novel drugs were approved, with half targeting cancer treatments, including new antibody-drug conjugates (ADCs) and targeted therapies. These approvals reflect a growing emphasis on precision oncology.

The third quarter saw an additional 16 novel drug approvals, with projections indicating over $16 billion in sales by 2030 for these products. Notably, gene therapies for conditions like familial hypercholesterolemia and Huntington's disease received breakthrough and fast track designations, highlighting the FDA's commitment to advancing personalized treatments.

Mergers and Acquisitions in Personalized Medicine:

The personalized medicine sector has witnessed a surge in mergers and acquisitions in 2025, underscoring the industry's growth and consolidation. Key transactions include:

Sanofi's Acquisition of Blueprint Medicines: Sanofi acquired Blueprint Medicines for approximately $9.5 billion, enhancing its portfolio in rare immunological diseases with treatments like Ayvakit for systemic mastocytosis.

Gilead's Purchase of Interius: Gilead acquired Interius for $350 million, advancing its in vivo CAR-T therapy capabilities.

AbbVie's Deal with Gilgamesh: AbbVie entered an up-to-$1.2 billion agreement with Gilgamesh to develop an investigational depression therapy, expanding its psychiatry portfolio.

These strategic moves reflect a broader trend of consolidation aimed at enhancing research and development capabilities in personalized medicine.

Regulatory Developments:

Regulatory bodies have been adapting to the complexities of personalized medicine. The FDA has been increasingly approving therapies based on genetic markers and companion diagnostics, facilitating more targeted and effective treatments. This trend is expected to continue, with a focus on gene-editing therapies and biologics.

Major Key Players:

Abbott
GE HealthCare.
Danaher Corporation (Cepheid, Inc.)
ASURAGEN, INC.
Exact Sciences Corporation
Illumina, Inc.
QIAGEN
Genentech, Inc.
Biogen
IBM.

Segments Covered in the Personalized Medicine Market:

By Product Type: Personalized Medicine Therapeutics, Personalized Medical Care.

By Application: Oncology, Neurology, Cardiology, Psychiatry, Immunology, Others.

By End-User: Hospitals & Specialty Care, Diagnostic Centers, Research & Academic Institutes, Others.

Regional Analysis:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=personalized-medicine-market

Chapter Outline

⏩ Market Overview: It contains five chapters, as well as information about the research scope, major manufacturers covered, market segments, Personalized Medicine market segments, study objectives, and years considered.

⏩ Market Landscape: The competition in the Global Personalized Medicine Market is evaluated here in terms of value, turnover, revenues, and market share by organization, as well as market rate, competitive landscape, and recent developments, transaction, growth, sale, and market shares of top companies.

⏩ Companies Profiles: The Global Personalized Medicine market's leading players are studied based on sales, main products, gross profit margin, revenue, price, and growth production.

⏩ Market Outlook by Region: The report goes through gross margin, sales, income, supply, market share, CAGR, and market size by region in this segment. North America, Europe, Asia Pacific, Middle East & Africa, and South America are among the regions and countries studied in depth in this study.

⏩ Market Segments: It contains the deep research study which interprets how different end-user/application/type segments contribute to the Personalized Medicine Market.

⏩ Market Forecast: Production Side: In this part of the report, the authors have focused on production and production value forecast, key producers forecast, and production and production value forecast by type.

⏩ Research Findings: This section of the report showcases the findings and analysis of the report.

⏩ Conclusion: This portion of the report is the last section of the report where the conclusion of the research study is provided.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Personalized Medicine Market in 2025?
◆ What is the projected growth rate of the Personalized Medicine Market through 2033?
◆ Who are the key players in the Personalized Medicine Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.